SCHEMBL19003422

SCHEMBL19003422

COCCOCCOCCOCCOCCOCCOCCOCCOS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.46
CA12 O43570 2/20 0.45
CA1 P00915 2/20 0.45
CA9 Q16790 2/20 0.45
GAA P10253 1/20 0.41
STAT3 P40763 1/20 0.40
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
MAPT P10636 1/20 0.39
PSMD10 O75832 1/20 0.39
CA2 P00918 1/20 0.38
CA3 P07451 1/20 0.38
CA6 P23280 1/20 0.38
CA5A P35218 1/20 0.38
CA7 P43166 1/20 0.38
CA5B Q9Y2D0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18998977 1.00 ALDH1A1 (0.47) ALDH1A1LMNAHPGDHTTCA12
SCHEMBL2329512 1.00 ALDH1A1 (0.47) ALDH1A1LMNAHPGDHTTCA12
SCHEMBL1218220 1.00 ALDH1A1 (0.47) ALDH1A1LMNAHPGDHTTCA12
SCHEMBL40774 1.00 ALDH1A1 (0.47) ALDH1A1LMNAHPGDHTTCA12
SCHEMBL361530 1.00 ALDH1A1 (0.47) ALDH1A1LMNAHPGDHTTCA12
SCHEMBL25398474 1.00 ALDH1A1 (0.47) ALDH1A1LMNAHPGDHTTCA12
SCHEMBL8282614 1.00 ALDH1A1 (0.47) ALDH1A1LMNAHPGDHTTCA12
SCHEMBL22262524 1.00 ALDH1A1 (0.47) ALDH1A1LMNAHPGDHTTCA12
SCHEMBL21877144 1.00 ALDH1A1 (0.47) ALDH1A1LMNAHPGDHTTCA12
SCHEMBL13169282 1.00 ALDH1A1 (0.47) ALDH1A1LMNAHPGDHTTCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250302973-A1 POLYMER CONJUGATES OF DRUGS WITH CENTRAL NERVOUS SYSTEM (CNS) EFFECTS AND PERIPHERAL NMDAR BLOCKING ACTIVITY AND/OR IMMUNE SYSTEM MODULATING EFFECTS MGGM LLC 2025-10-02 US disclosed
US-20230322821-A1 QUINOLINONE DERIVATIVE COMPOUND SELECTIVELY BINDING TO CYSTEINE, PEPTIDE CONJUGATE THEREOF, AND ANTIBODY-DRUG CONJUGATE COMPRISING SAME INSTITUTE FOR BASIC SCIENCE (KR) 2023-10-12 US disclosed
US-20230241241-A1 CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-08-03 US disclosed
US-20230241241-A1 CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-08-03 US disclosed
US-20230174520-A1 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives GRUENENTHAL GMBH (DE) 2023-06-08 US disclosed
US-20230115871-A1 A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS HANGZHOU DAC BIOTECH CO., LTD (CN) 2023-04-13 US disclosed
US-20230057350-A1 A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-02-23 US disclosed
WO-2022109492-A1 PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS GOSSAMER BIOSERVICES, INC. (US) 2022-05-27 WO disclosed
CN-114040779-A Conjugates of cell binding molecules containing branched linkers and cytotoxic agents 杭州多禧生物科技有限公司 2022-02-11 CN disclosed
US-20210179592-A1 3-((HETERO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES Grünenthal GmbH (DE) 2021-06-17 US disclosed
US-20210164005-A1 METHODS FOR INDUCING BIOORTHOGONAL REACTIVITY UNIVERSITY OF DELAWARE (US) 2021-06-03 US disclosed
US-10875840-B2 Methods for inducing bioorthogonal reactivity UNIVERSITY OF DELAWARE (US) 2020-12-29 US disclosed
US-20200399252-A1 3-((HETERO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES Grünenthal GmbH (DE) 2020-12-24 US disclosed
US-10829480-B2 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-l,3-diaza-spiro-[4.5]-decane derivatives GRUENENTHAL GMBH (DE) 2020-11-10 US disclosed
EP-3402784-B1 3-((HETERO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES GRUENENTHAL GMBH (DE) 2020-03-11 EP disclosed
EP-3402784-A1 3-((HETERO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES Grünenthal GmbH (DE) 2018-11-21 EP disclosed
US-20180327392-A1 3-((HETERO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES Grünenthal GmbH (DE) 2018-11-15 US disclosed
WO-2017121648-A1 3-((HETERO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES Grünenthal GmbH (DE) 2017-07-20 WO disclosed
US-20170197947-A1 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives GRUENENTHAL GMBH (DE) 2017-07-13 US disclosed
WO-2017106427-A1 METHODS FOR INDUCING BIOORTHOGONAL REACTIVITY FOX JOSEPH (US) 2017-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174520-A1 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives OPRK1, OPRD1, ARRB1 ALDH1A1 398/4885LMNA 2604/4885HPGD 1043/4885
US-20210179592-A1 3-((HETERO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES OPRK1, OPRD1, ARRB1 ALDH1A1 398/4885LMNA 2604/4885HPGD 1043/4885
US-20230057350-A1 A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS BTN3A1, ANTXR2, CLTA ALDH1A1 4011/4885LMNA 1602/4885HPGD 4664/4885
US-20170197947-A1 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives OPRK1, OPRD1, ARRB1 ALDH1A1 398/4885LMNA 2604/4885HPGD 1043/4885
US-20200399252-A1 3-((HETERO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES OPRK1, OPRD1, ARRB1 ALDH1A1 398/4885LMNA 2604/4885HPGD 1043/4885
US-20230115871-A1 A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS CD2BP2, EPCAM, CD74 ALDH1A1 2397/4885LMNA 2119/4885HPGD 3960/4885
US-20250302973-A1 POLYMER CONJUGATES OF DRUGS WITH CENTRAL NERVOUS SYSTEM (CNS) EFFECTS AND PERIPHERAL NMDAR BLOCKING ACTIVITY AND/OR IMMUNE SYSTEM MODULATING EFFECTS GRIN3A, GRIN1, GRIN3B ALDH1A1 4106/4885LMNA 4649/4885HPGD 2318/4885
US-20180327392-A1 3-((HETERO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES OPRK1, OPRD1, ARRB1 ALDH1A1 398/4885LMNA 2604/4885HPGD 1043/4885
US-10829480-B2 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-l,3-diaza-spiro-[4.5]-decane derivatives OPRD1, OPRK1, OPRL1 ALDH1A1 473/4885LMNA 2171/4885HPGD 1113/4885
US-10875840-B2 Methods for inducing bioorthogonal reactivity CBR1, CBR3, DUOX1 ALDH1A1 204/4885LMNA 4557/4885HPGD 158/4885
US-20230322821-A1 QUINOLINONE DERIVATIVE COMPOUND SELECTIVELY BINDING TO CYSTEINE, PEPTIDE CONJUGATE THEREOF, AND ANTIBODY-DRUG CONJUGATE COMPRISING SAME QPCT, GCLC, QPCTL ALDH1A1 1061/4885LMNA 4878/4885HPGD 2677/4885
US-20230241241-A1 CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS CD4, DCLRE1A, TOP1 ALDH1A1 3405/4885LMNA 493/4885HPGD 3435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.